natgillin/translations-raw huggingface dataset:
Data were provided, based on the pharmacokinetics of closantel, that demonstrated that the formulation differences, and thereby the potential differences in the rates of absorption from the injection site, would not affect the overall elimination from the edible tissues, other than from the injection site itself. 
Na podlagi farmakokinetike klozantela so bili predloženi podatki, ki so pokazali, da razlike v formulacijah in s tem morebitne razlike v hitrosti absorpcije z mesta injiciranja ne vplivajo na celokupno izločanje iz tkiv, namenjenih prehrani, razen s samega mesta injiciranja.
The CVMP was requested to review all available residue depletion data for the veterinary medicinal products containing 50 mg closantel per ml (as a single active substance), presented as a solution for injection for subcutaneous use in sheep and recommend withdrawal periods for meat and offal derived from treated sheep. 
Odbor CVMP je bil zaprošen, naj pregleda vse razpoložljive podatke o izločanju ostankov zdravil za uporabo v veterinarski medicini, ki vsebujejo 50 mg klozantela na ml (kot posamezno učinkovino), v obliki raztopine za injiciranje za subkutano uporabo pri ovcah in priporoči obdobja karence za meso in organe, pridobljene iz zdravljenih ovac.
• The tissue-specific withdrawal period determined from Study 1 for liver was 28 days longer than that for injection sites, which leaves a suitably long time for any additional injection site residues to deplete before the 107-day withdrawal period is complete. 
• Tkivno specifična karenca, določena za jetra v študiji 1, je bila za 28 dni daljša od karence za mesta injiciranja, kar pušča primerno dolg čas, da se pred koncem 107-dnevne karence izločijo vsi morebitni preostali ostanki zdravila.
It has been noted that there are different approved withdrawal periods for sheep (meat and offal) for veterinary medicinal products containing 50 mg closantel per ml (as a single active substance) presented as solution for injection for subcutaneous use in sheep across the EU, i.e., between 28 days and 107 days. 
Ugotovljeno je bilo, da so obdobja karence za ovce (meso in organe) za zdravila, ki vsebujejo 50 mg klozantela na ml (kot edino učinkovino), v obliki raztopine za injiciranje za subkutano uporabo pri ovcah med državami članicami različna, tj. od 28 do 107 dni.
The product was administered via subcutaneous injection to sheep, at the single recommended dose of 5 mg closantel per kg body weight. 
To zdravilo so dajali ovcam s subkutano injekcijo v enkratnem priporočenem odmerku 5 mg klozantela na kg telesne mase.
• The tissue-specific withdrawal period determined from Study 1 for liver was 28 days longer than for injection sites, leaving a long time for any additional injection site residues to deplete before the 107-day withdrawal period is complete. 
• Tkivno specifična karenca, določena za jetra v študiji 1, je bila za 28 dni daljša od karence za mesta injiciranja, kar pušča dovolj časa, da se pred iztekom 107-dnevne karence izločijo vsi morebitni preostali ostanki zdravila.
Not authorised for use in ewes producing milk for human consumption including during the dry period. 
Ni dovoljena uporaba pri ovcah mlekaricah, ki dajejo mleko, namenjeno za prehrano ljudi.
Santiola 50 mg/ml Solution for Injection for Cattle and Sheep sheep sheep: subcutaneous 
Santiola 50 mg/ml Solution for Injection for Cattle and Sheep ovce ovce: subkutano
A GLP-compliant residue depletion study in sheep was submitted, conducted with the veterinary medicinal product ‘Flukiver 5%', a product containing 50 mg closantel per ml. 
Predložena je bila z dobro laboratorijsko prakso skladna študija o izločanju ostankov pri ovcah, izvedena z zdravilom Flukiver 5 % za uporabo v veterinarski medicini, ki vsebuje 50 mg klozantela na ml.
The available data demonstrate that the liver is the withdrawal period determining tissue and that the rate of elimination from edible tissues would not be influenced by the rate of absorption from the injection site and thereby impacted by product formulation. 
Razpoložljivi podatki kažejo, da so jetra tkivo, ki določa karenco, in da hitrost absorpcije z mesta injiciranja in s tem formulacija zdravila ne vpliva na hitrost izločanja iz tkiv, namenjenih prehrani.
A GLP-compliant residue depletion study in sheep was submitted, conducted with the veterinary medicinal product ‘Endoex Solucion Injectable', a product containing 50 mg closantel per ml. 
Predložena je bila z dobro laboratorijsko prakso skladna študija o izločanju ostankov pri ovcah, izvedena z zdravilom Endoex Solucion Injectable za uporabo v veterinarski medicini, ki vsebuje 50 mg klozantela na ml. Ovcam so zdravilo dajali s subkutano injekcijo v enkratnem priporočenem odmerku 5 mg klozantela na kg telesne mase.
It was also shown that, in general, the higher the volume of injection, the slower the rate of absorption from the injection site. 
Dokazali so tudi, da se hitrost absorpcije z mesta injiciranja zmanjšuje s povečevanjem injiciranega volumna.
powder: 15 mg 1 vial 
15 mg prašek za raztopino za infundiranje intravenska uporaba steklena viala Prašek: 15 mg 1 x 10 ml viala
This summary was last updated in 09-2007 
Ta povzetek je bil nazadnje posodobljen 09-2007.
The marketing authorisation was renewed on 11-2006. 
Dovoljenje za promet z zdravilom je bilo podaljšano dne 11-2006.
Other information about Protopy: 
Druge informacije o zdravilu Protopy:
The European Commission granted a marketing authorisation valid throughout the European Union, for Protopy to Astellas Pharma GmbH on 28 February 2002. 
Evropska komisija je dovoljenje za promet z zdravilom Protopy, veljavno po vsej Evropski uniji, odobrila družbi Astellas Pharma GmbH dne 28. februarja 2002.
Protopy should not be used in children under 2 years of age. 
Zdravila Protopy se ne sme uporabljati za otroke mlajše od 2 let.
Treatment should be started as twice a day for up to three weeks. 
Zdravljenje je treba začeti z uporabo dvakrat dnevno do tri tedne.
Tacrolimus has been used since the mid-1990's to help prevent rejection in transplant patients (when the immune system attacks the transplanted organ). 
Takrolimus se od sredine 1990-ih uporablja za preprečevanje zavrnitve pri bolnikih po presaditvi (ko imunski sistem napade presajeni organ).
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) PROTOPY EPAR summary for the public 
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) PROTOPY Povzetek EPAR za javnost
The safety and effectiveness of Protopy has been studied in more than 13,500 patients treated with tacrolimus ointment in clinical trials. 
Varnost in učinkovitost zdravila Protopy so preučili pri več kot 13.500 bolnikih, ki so bili v kliničnih preskušanjih zdravljeni z mazilom, ki je vsebovalo takrolimus.
In the longer study, Protopy could be used repeatedly without losing its effectiveness. 
V daljši raziskavi so lahko zdravilo Protopy uporabili v ponovitvah brez zmanjšanja učinkovitosti.
Generally, improvement is seen within one week of starting treatment, and if there is no improvement after 2 weeks, the doctor needs to look at more treatment options. 
Če po 2 tednih zdravljenja ni znakov izboljšanja, mora zdravnik pretehtati druge možnosti zdravljenja.
The exact way that Protopy works in atopic dermatitis is not yet fully understood. 
Natančen mehanizem delovanja zdravila Protopy pri atopičnem dermatitisu še ni popolnoma znan.
Protopy is a white to slightly yellowish ointment that contains either 0.1% or 0.03% of the active ingredient tacrolimus. 
Zdravilo Protopy je belo do rahlo rumenkasto mazilo, ki vsebuje bodisi 0,1 % ali 0,03 % zdravilne učinkovine takrolimus.
What benefit has Protopy shown during the studies? 
Kakšne koristi je zdravilo Protopy izkazalo med raziskavami?
What is the risk associated with Protopy? 
Kakšna tveganja so povezana z zdravilom Protopy?
In adults, treatment should be started with Protopy 0.1% twice a day and treatment should be continued until the skin is clear. 
Pri odraslih je treba zdravljenje začeti z zdravilom Protopy 0,1% dvakrat dnevno in ga nadaljevati, dokler spremembe ne izginejo.
The main measure of effectiveness was the improvement in the eczema seen at the end of the study (3 or 12 weeks) using a scoring system (the modified Eczema Area and Severity Index) that looks at all the symptoms of atopic dermatitis. 
Glavno merilo učinkovitosti je bilo izboljšanje ekcema na koncu raziskave (3 ali 12 tednov) na podlagi sistema točkovanja, imenovanega modificirani indeks površine in resnosti ekcema (Modified Eczema Area and Severity Index), ki zajema vse simptome atopičnega dermatitisa.
Protopy should be prescribed by a doctor with experience in the diagnosis and treatment of atopic dermatitis. 
Zdravilo Protopy lahko predpišejo le zdravniki, ki imajo izkušnje s postavljanjem diagnoze in zdravljenjem atopičnega dermatitisa.
Tacrolimus, the active substance in Protopy, is an immunomodulator, this means that it works on the immune system (the body's natural defences). 
Takrolimus, zdravilna učinkovina zdravila Protopy, je imunomodulator, kar pomeni, da deluje na imunski sistem (naravne obrambne mehanizme telesa).
Protopy should not be used continuously. 
Zdravilo Protopy ni za stalno uporabo.
The lower strength of Protopy (0.03%) may also be used for this condition in children (2 years of age and above) who do not respond well to, or do not tolerate usual treatments. 
Oblika zdravila Protopy z manjšo jakostjo (0,03 %) se lahko uporablja tudi za zdravljenje tega stanja pri otrocih (starih 2 leti ali več), ki se neustrezno odzivajo na običajne terapije ali pa jih ne prenašajo.
Protopy should not be used in people who may be hypersensitive (allergic) to tacrolimus or to any of the other ingredients. 
Zdravila Protopy ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) takrolimus ali katerokoli drugo sestavino zdravila.
In atopic dermatitis, an over-reaction of the skin's immune system causes skin inflammation (itchiness, redness, dryness). 
atopičnem dermatitisu čezmerna reakcija imunskega sistema v koži povzroči vnetje kože (srbečico, pordelost, izsušenost).
If possible, patients should use less frequent applications, or the lower strength as their condition improves. 
Ko se stanje izboljša, naj bolniki uporabljajo zdravilo redkeje ali v obliki z manjšo jakostjo, če je možno.
The most common side effects (seen in more than 1 patient in 10) are burning sensation and itching at the application site. 
Najpogostejša neželena učinka (opažena pri več kot 1 bolniku od 10) sta bila pekoč občutek in srbečica ne mestu uporabe.
Another study has also looked at the use of Protopy for up to 4 years in about 800 patients. 
V drugi raziskavi so pri 800 bolnikih preverili uporabo zdravila Protopy, ki je trajala 4 leta.
Why has Protopy been approved? 
Zakaj je bilo zdravilo Protopy odobreno?
In children, only the lowest strength Protopy 0.03% should be used. 
Pri otrocih je treba uporabiti obliko zdravila Protopy z manjšo jakostjo (0,03 %).
Tacrolimus calms down the immune system, and this helps relieve the skin inflammation and the itch. 
Takrolimus umiri imunski sistem, kar olajša vnetje kože in srbečico.
They recommended that Protopy be given marketing authorisation. 
Odbor je za zdravilo Protopy priporočil odobritev dovoljenja za promet z zdravilom.
Protopy is used for the treatment of moderate to severe atopic dermatitis (eczema, an itchy red rash of the skin- atopic means that is linked to an allergy) in adults who do not respond well or do not tolerate usual treatments. 
Zdravilo Protopy se uporablja za zdravljenje zmernega do hudega atopičnega dermatitisa (ekcema, srbečega kožnega izpuščaja s pordelostjo; atopičen pomeni, da je povezan z alergijo) pri odraslih, ki se na običajne terapije ne odzovejo ustrezno ali jih ne prenesejo.
Protopy was significantly more effective than either of the 2 hydrocortisone preparations at producing improvements in the modified Eczema Area and Severity Index, although it also produced more burning than hydrocortisone. 
Zdravilo Protopy je bilo statistično značilno učinkovitejše od obeh hidrokortizonskih pripravkov pri spodbujanju napredka po indeksu površine in resnosti ekcema, čeprav je v več primerih povzročil pekoč občutek kot hidrokortizon.
Doctors must be aware that a very small number of patients using the medicine have developed cancer (skin cancer, lymphoma). 
Zelo majhno število bolnikov je imelo raka (kožnega raka, limfom) v času uporabe zdravila.
Each affected area is treated with Protopy until the skin is clear and then treatment should be stopped. 
Vsak prizadeti predel kože je treba z zdravilom Protopy zdraviti, dokler spremembe ne izginejo.
The Committee for Medicinal products for Human Use (CHMP) decided that Protopy's benefits are greater than its risks for the treatment of moderate to severe atopic dermatitis in adults and children over the age of 2 who are not adequately responsive to or are intolerant of conventional therapies. 
Odbor za zdravila za uporabo v humani medicini (CHMP) meni, da so koristni učinki zdravila Protopy pri zdravljenju zmernega do hudega atopičnega dermatitisa pri odraslih in otrocih, starih 2 leti ali več, ki se neustrezno odzivajo na običajne terapije ali pa jih ne prenašajo, večji od z njim povezanih tveganj.
Afterwards, application should be reduced to once a day until the skin is clear. 
Potem je treba pogostnost uporabe zmanjšati na enkrat dnevno in zdravilo uporabljati, dokler spremembe ne izginejo.
The full EPAR for Protopy is available here. 
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Protopy je na voljo tukaj.
The ointment should be applied as a thin layer to affected areas of the skin. 
Na prizadete predele kože je treba nanesti tanko plast mazila.
What is Protopy used for? 
Za kaj se zdravilo Protopy uporablja?
The six main clinical studies involved 1,202 adults (over the age of 16) and 1,535 children (aged 2 to 16 years of age), and Protopy was compared either with placebo (a dummy treatment, the ointment base) or with a topical corticosteroid often used for eczema (hydrocortisone butyrate in adults, hydrocortisone acetate in children). 
V šestih glavnih kliničnih raziskavah je sodelovalo 1202 odraslih bolnikov (starejših od 16 let) in 1535 otrok (starih od 2 do 16 let).
How has Protopy been studied? 
Kako je bilo zdravilo Protopy raziskano?
What is Protopy? 
Kaj je zdravilo Protopy?
How does Protopy work? 
Kako zdravilo Protopy deluje?
For the full list of all the side effects reported with Protopy, please see the Package Leaflet. 
Celovit opis neželenih učinkov, o katerih so poročali pri uporabi zdravila Protopy, najdete v Navodilih za uporabo.
How is Protopy used? 
Kako se zdravilo Protopy uporablja?
However, doctors must ensure that the medicine is used appropriately. 
Povezava z zdravilom Protopy ni bila dokazana, vendar se morajo zdravniki tega zavedati in zagotoviti, da se zdravilo uporablja pravilno ter da bolnika spremljajo med zdravljenjem.
Treatment may continue up to 14 days 
2 Zdravljenje se lahko nadaljuje do 14 dni.
Less than 10 
Manj kot 10
Such reactions may be life-threatening. 
Takšne reakcije so lahko smrtno nevarne.
Children or adolescents 
Otroci ali mladostniki
If this happens, do not take medicines that stop or slow bowel movement. 
Če se to zgodi, ne jemljite zdravil, ki ustavijo ali upočasnijo gibanje črevesa.
Meropenem alone is not known to interact with active transport systems. 
Za sam meropenem ni znano nobeno medsebojno delovanje z aktivnimi transportnimi sistemi.
Unknown (cannot be estimated from the available data) 
Neznana (ni mogoče oceniti iz razpoložljivih podatkov)
Your doctor will decide how many days of treatment are needed, depending on the type of infection. 
Vaš zdravnik bo določil, koliko dni mora trajati vaše zdravljenje, odvisno od vrste okužbe.
20 to 39 
Od 20 do 39
This is because it is not known if the medicine is safe to use in these age groups. 
Ni namreč znano, ali je uporaba zdravila v tej starostni skupini varna.
Small amounts of this medicine may pass into the breast milk and it may affect the baby. 
Majhne količine tega zdravila bi lahko prehajale v mleko in vplivale na otroka.
New infection 
Nova okužba
It is particularly important to tell your doctor if you are taking any of the following medicines: 
Še zlasti je pomembno, da obvestite zdravnika, če jemljete katero koli od naslednjih zdravil:
Because a risk to the newborns/infants cannot be excluded, breastfeeding must be discontinued prior to initiating therapy. 
Ker tveganja za dojene novorojence/otroke ne moremo izključiti, je treba pred začetkom zdravljenja prenehati z dojenjem.
The reconstituted vial should be further diluted immediately. 
Rekonstituirano vialo je treba takoj dodatno razredčiti.
This medicine can affect your liver. 
To zdravilo lahko vpliva na jetra.
• Swelling of the tongue, face, lips or throat 
• oteklost jezika, obraza, ustnic ali žrela
MARKETING AUTHORISATION NUMBER(S) EU/1/18/1334/001 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/18/1334/001
Within each System Organ Class, undesirable effects are presented in order of decreasing seriousness. 
V vsakem organskem sistemu so neželeni učinki razvrščeni po padajoči resnosti.
Meropenem is mostly eliminated unchanged. 
Meropenem se večinoma izloči v nespremenjeni obliki.
Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows: 
Mejne vrednosti minimalne zaviralne koncentracije (MZK), ki jih je določil Evropski odbor za testiranje protimikrobne občutljivosti (EUCAST), so naslednje:
The safety and efficacy of meropenem/vaborbactam in children and adolescents younger than 18 years of age have not yet been established. 
Varnost in učinkovitost meropenema/vaborbaktama pri otrocih in mladostnikih, mlajših od 18 let, še nista dokazani.
This may affect your ability to drive, use tools or machines. 
To lahko vpliva na vašo sposobnost za vožnjo, uporabo orodij in upravljanje strojev.
If you have kidney problems, your doctor may lower your dose. 
Če imate težave z ledvicami, vam bo zdravnik morda zmanjšal odmerek.
• medicines that weaken your body's immune system, such as tacrolimus, everolimus and cyclosporine 
• zdravila, ki oslabijo imunski sistem telesa, kot so takrolimus, everolimus in ciklosporin;
• Peptostreptococcus species (including P. micros, P anaerobius, P. magnus) 
• Peptostreptococcus species (vključno s P. micros, P anaerobius, P. magnus)
Your doctor will monitor you closely for any new infections and give you another treatment if necessary. 
Vaš zdravnik bo pozoren na morebitne nove okužbe in vam bo po potrebi predpisal drugo zdravilo.
7 to 14 days 
3 ure od 7 do 14 dni
About 25% of the administered dose is eliminated as the inactive open ring form. 
Približno 25 % uporabljenega odmerka se izloči v neaktivni obliki odprtega obroča.
Adverse reactions are classified according to frequency and System Organ Class. 
Neželeni učinki so razvrščeni glede na pogostnost in organski sistem.
3 hours 
3 ure
If a severe allergic reaction occurs, treatment with Vaborem must be discontinued immediately and adequate emergency measures must be initiated. 
Če nastopi huda alergijska reakcija, je treba zdravljenje z zdravilom Vaborem nemudoma prekiniti in uvesti ustrezne nujne ukrepe.
It is unknown whether a potential interaction would result in increased or decreased plasma concentrations, and thus patients should be monitored both for signs of toxicity and lack of efficacy of the narrow therapeutic index drug. 
Ni znano, ali bi morebitno medsebojno delovanje povzročilo zvišane ali znižane koncentracije v plazmi, zato je treba bolnike spremljati glede znakov toksičnosti in pomanjkanja učinkovitosti zdravila z ozkim terapevtskim indeksom.
From a microbiological point of view, the medicinal product should be used immediately upon reconstitution and dilution. 
Z mikrobiološkega stališča je treba zdravilo uporabiti takoj po rekonstituciji in razredčitvi.
Vaborem should not be used in children or adolescents under 18 years of age. 
Zdravila Vaborem ne smejo uporabljati otroci in mladostniki, mlajši od 18 let.
1 As calculated using the Cockcroft-Gault formula 
1 Izračunano po Cockcroft-Gaultovi formuli.
• oral anticoagulant medicines, such as warfarin (used to treat or prevent blood clots) 
• peroralna antikoagulacijska zdravila, kot je varfarin (uporabljajo se za zdravljenje ali preprečevanje krvnih strdkov);
Minimum Inhibitory Concentrations (mg/l) Susceptible 
Minimalne zaviralne koncentracije (mg/l) Občutljivi
Antibacterial activity in combination with other antibacterial agents 
Protibakterijsko delovanje v kombinaciji z drugimi protibakterijskimi učinkovinami
The use of meropenem/vaborbactam may result in the overgrowth of non-susceptible organisms, which may require interruption of treatment or other appropriate measures. 
Uporaba meropenema/vaborbaktama lahko povzroči razrast neobčutljivih organizmov, zato bodo morda potrebni prekinitev zdravljenja ali drugi ustrezni ukrepi.
The number of vials used for a single dose will depend on the creatinine clearance (CrCl) of the patient. 
Število vial, ki se uporabijo za posamezen odmerek, je odvisno od bolnikovega očistka kreatinina (CrCl).
• you are allergic to other carbapenem antibiotics (the group to which meropenem belongs). 
• ste alergični na druge karbapenemske antibiotike (skupina, v katero spada meropenem),
Approximately 75 to 95% of vaborbactam is excreted unchanged in the urine over a 24 - 48 hour period. 
Približno 75-95 % vaborbaktama se v nespremenjeni obliki izloči z urinom v 24-48 urah.
• A positive result from a test called“Coombs”used to identify haemolytic anemia (see above) or reaction of your immune system to Vaborem 
• Pozitiven rezultat t. i. »Coombsovega testa«, ki se uporablja za ugotavljanje hemolitične anemije (glejte zgoraj) ali reakcije vašega imunskega sistema na zdravilo Vaborem
The risk may vary with the underlying infection, age and general status of the patient so that the contribution of the antibacterial agent to the increase in international normalised ratio (INR) is difficult to assess. 
Tveganje se razlikuje glede na okužbo, starost in splošno stanje bolnika, zato je v teh okoliščinah težko oceniti vpliv protibakterijske učinkovine na povečanje mednarodno normaliziranega razmerja (INR).
The powder for concentrate for solution for infusion must be reconstituted and further diluted prior to use. 
Prašek za koncentrat za raztopino za infundiranje je treba pred uporabo rekonstituirati in razredčiti.
Approximately 40-60% of a meropenem dose is excreted unchanged within 24 - 48 hours with a further 25% recovered as the microbiologically inactive hydrolysis product. 
Približno 40-60 % odmerka meropenema se izloči v nespremenjeni obliki v 24-48 urah, medtem ko se dodatnih 25 % odmerka izloči kot mikrobiološko neaktiven produkt hidrolize.
If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before receiving this medicine. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom, preden dobite to zdravilo.
The effects of meropenem/vaborbactam on fertility in humans have not been studied. 
Učinkov meropenema/vaborbaktama na plodnost pri ljudeh niso preučili.
• Haemolytic anaemia (a condition where red blood cells are damaged and reduced in number), which may make you feel tired and turn your skin and eyes yellow 
• hemolitična anemija (bolezen, pri kateri so rdeče krvne celice poškodovane, njihovo število pa zmanjšano), zaradi česar se lahko počutite utrujene ter imate porumenelo kožo in oči
Medicinal products that inhibit peristalsis should not be given. 
Zdravil, ki zavirajo peristaltiko, se ne sme dajati.
10 to 19 
Od 10 do 19
<1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); unknown (cannot be estimated from the available data). 
Pogostnost je opredeljena kot: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥1/10.000 do < 1/ 1.000); zelo redki (< 1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Infections due to aerobic Gram-negative organisms in patients with limited treatment options 
Okužbe zaradi aerobnih gramnegativnih organizmov pri bolnikih z omejenimi možnostmi zdravljenja